Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.10.06.21264651: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Model Structure and Calculations: An economic model was developed in Microsoft® Excel to estimate the clinical benefits and budget impact of adding lenzilumab to SOC versus SOC alone for newly hospitalized patients with COVID-19 pneumonia. Microsoft® Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected …SciScore for 10.1101/2021.10.06.21264651: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Model Structure and Calculations: An economic model was developed in Microsoft® Excel to estimate the clinical benefits and budget impact of adding lenzilumab to SOC versus SOC alone for newly hospitalized patients with COVID-19 pneumonia. Microsoft® Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Despite these limitations, a scenario analysis was conducted to assess potential long-term cost savings with lenzilumab by incorporating rehospitalizations over one year after initial hospitalization into the analysis. The results indicated that adding lenzilumab to SOC may result in total cost savings of $5,154 associated with reduction in IMV use during the index hospitalization. The sensitivity analyses suggested that model results were robust to changes reflecting a reasonable level of uncertainty (±10%) in key inputs including hospital resource costs, patient distributions to different levels of care, and time to recovery. Based on these analyses, time to recovery had the greatest impact on the results of the model. Decreasing the time to recovery by 10% for the lenzilumab plus SOC arm resulted in an 88.8% increase in cost savings relative to the base case. By comparison varying hospital resource costs and patient distributions to different levels of care had less impact on the cost savings associated with adding lenzilumab to SOC. As with any model-based analysis, this study had several limitations. The analysis used data from the LIVE-AIR Phase 3 clinical trial, which would not be fully generalizable to a real-world US hospital population. Patient data from LIVE-AIR were censored after 28 days following trial enrollment. This is noteworthy because patients with COVID-19 who are critically ill and/or who require IMV typically have extended time to recovery, sometimes be...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04351152 Active, not recruiting Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
